{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T04:12:34Z","timestamp":1748751154999,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00508-015-0912-6","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T07:38:17Z","timestamp":1449733097000},"page":"414-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure"],"prefix":"10.1007","volume":"128","author":[{"given":"Mattias","family":"Mandorfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit A.","family":"Payer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian C.","family":"Aichelburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Grabmeier-Pfistershammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"issue":"10","key":"912_CR1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","volume":"24","author":"C Smith","year":"2010","unstructured":"Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24(10):1537\u201348.","journal-title":"AIDS"},{"issue":"1","key":"912_CR2","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","volume":"44","author":"MJ Alter","year":"2006","unstructured":"Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(Supplement 1):S6\u2013S9.","journal-title":"J Hepatol"},{"issue":"4","key":"912_CR3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","volume":"30","author":"Y Benhamou","year":"1999","unstructured":"Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054\u20138.","journal-title":"Hepatology"},{"issue":"4","key":"912_CR4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"CS Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562\u20139.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"912_CR5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/cis694","volume":"55","author":"G Wandeler","year":"2012","unstructured":"Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55(10):1408\u201316.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"912_CR6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/gut.2010.217166","volume":"60","author":"EC Thomson","year":"2011","unstructured":"Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60(6):837\u201345.","journal-title":"Gut"},{"issue":"4","key":"912_CR7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","volume":"25","author":"European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel","year":"2011","unstructured":"European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011;25(4):399\u2013409.","journal-title":"AIDS"},{"key":"912_CR8","unstructured":"Battegay M, Mulcahy F, Geretti AM, et al. European AIDS Clinical Society (EACS) Guidelines Version 7.1: European AIDS Clinical Society (EACS). 2014. http:\/\/www.eacsociety.org\/Portals\/0\/GUIDELINES\/EnglishPDF\u2014Version7.1.pdf . Accessed: 7 June 2015"},{"issue":"4","key":"912_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcv.2011.08.020","volume":"52","author":"J Dorward","year":"2011","unstructured":"Dorward J, Garrett N, Scott D, et al. Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. J Clin Virol. 2011;52(4):367\u20139.","journal-title":"J Clin Virol"},{"issue":"10","key":"912_CR10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1089\/aid.2011.0289","volume":"28","author":"M Laguno","year":"2012","unstructured":"Laguno M, Martinez-Rebollar M, Perez I, et al. Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses. 2012;28(10):1294\u2013300.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"912_CR11","doi-asserted-by":"crossref","unstructured":"Mandorfer M, Schwabl P, Steiner S, et al. Advances in the management of HIV\/HCV coinfection. Hepatol Int. 2016; (In press).","DOI":"10.1007\/s12072-015-9691-4"},{"issue":"2","key":"912_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","volume":"159","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86\u201396.","journal-title":"Ann Intern Med"},{"issue":"7","key":"912_CR13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","volume":"13","author":"M Sulkowski","year":"2013","unstructured":"Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597\u2013605.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"912_CR14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/infdis\/jiu516","volume":"211","author":"M Mandorfer","year":"2015","unstructured":"Mandorfer M, Steiner S, Schwabl P, et al. Response-Guided Boceprevir-based Triple Therapy in HIV\/HCV-coinfected Patients: the HIVCOBOC-RGT Study. J Infect Dis. 2015;211(5):729\u201335.","journal-title":"J Infect Dis"},{"issue":"6","key":"912_CR15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/cid\/cit799","volume":"58","author":"DS Fierer","year":"2014","unstructured":"Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58(6):873\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"912_CR16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jvh.12348","volume":"22","author":"C Boesecke","year":"2015","unstructured":"Boesecke C, Rockstroh JK. How will we manage acute HCV in men having sex with men in the era of all oral therapy? J Viral Hepat. 2015;22(1):2\u20137.","journal-title":"J Viral Hepat"},{"issue":"4","key":"912_CR17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cgh.2010.07.019","volume":"9","author":"AF Stattermayer","year":"2011","unstructured":"Stattermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(4):344\u201350.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11\u201312","key":"912_CR18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00508-012-0190-5","volume":"124","author":"T Reiberger","year":"2012","unstructured":"Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography\u2013a large single center experience. Wien Klin Wochenschr. 2012;124(11\u201312):395\u2013402.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"912_CR19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/liv.12623","volume":"35","author":"P Schwabl","year":"2015","unstructured":"Schwabl P, Bota S, Salzl P, et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int. 2015;35(2):381\u201390.","journal-title":"Liver Int"},{"issue":"2","key":"912_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Castera","year":"2005","unstructured":"Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343\u201350.","journal-title":"Gastroenterology"},{"issue":"1","key":"912_CR21","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60067-7","volume":"58","author":"K Rutter","year":"2013","unstructured":"Rutter K, Ferlitsch A, Maieron A, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease\u2014predictive factors for sepsis. J Hepatol. 2013;58(Supplement 1):S30.","journal-title":"J Hepatol"},{"issue":"3","key":"912_CR22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","volume":"59","author":"C Hezode","year":"2013","unstructured":"Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)\u2014NCT01514890. J Hepatol. 2013;59(3):434\u201341.","journal-title":"J Hepatol"},{"issue":"3","key":"912_CR23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"912_CR24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/cid\/ciu675","volume":"59","author":"D Dieterich","year":"2014","unstructured":"Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) With Pegylated Interferon\/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: a Phase 3 Study. Clin Infect Dis. 2014;59(11):1579\u201387.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"912_CR25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353\u201361.","journal-title":"JAMA"},{"issue":"9973","key":"912_CR26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","volume":"385","author":"JM Molina","year":"2015","unstructured":"Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385(9973):1098\u2013106.","journal-title":"Lancet"},{"issue":"8","key":"912_CR27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714\u201325.","journal-title":"N Engl J Med"},{"issue":"12","key":"912_CR28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","volume":"313","author":"A Osinusi","year":"2015","unstructured":"Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232\u20139.","journal-title":"JAMA"},{"issue":"8","key":"912_CR29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373(8):705\u201313.","journal-title":"N Engl J Med"},{"issue":"12","key":"912_CR30","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223\u201331.","journal-title":"JAMA"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-015-0912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-015-0912-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-015-0912-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T18:46:52Z","timestamp":1748717212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-015-0912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":30,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1007\/s00508-015-0912-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2015,12,10]]}}}